Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.

× No keyword cloud information.

20 in total

Review 1. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors: Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal: Nat Rev Neurol Date: 2015-09-15 Impact factor: 42.937

2. Effects of fingolimod treatments on alanine transaminase and aspartate transaminase levels in patients with multiple sclerosis.

Authors: Saeid Sadeghi Joni; Masoumeh Cheshmavar; Pouria Shoureshi; Zohreh Zamani; Niusha Taoosi; Morteza Akbari; Mahdieh Afzali
Journal: Int J Physiol Pathophysiol Pharmacol Date: 2020-06-15

3. Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients.

Authors: A Ghezzi; M A Rocca; D Baroncini; P Annovazzi; M Zaffaroni; G Minonzio; G Comi; M Filippi
Journal: J Neurol Date: 2012-11-16 Impact factor: 4.849

Review 4. Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.

Authors: Jiwon Oh; Paul W O'Connor
Journal: CNS Drugs Date: 2013-08 Impact factor: 5.749

5. Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.

Authors: Loredana La Mantia; Valentina Prone; Maria Raffaella Marazzi; Cristina Erminio; Alessandra Protti
Journal: Neurol Sci Date: 2014-04-23 Impact factor: 3.307

Review 6. [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Authors: L Klotz; A Berthele; W Brück; A Chan; P Flachenecker; R Gold; A Haghikia; K Hellwig; B Hemmer; R Hohlfeld; T Korn; T Kümpfel; M Lang; V Limmroth; R A Linker; U Meier; S G Meuth; F Paul; A Salmen; M Stangel; B Tackenberg; H Tumani; C Warnke; M S Weber; T Ziemssen; F Zipp; H Wiendl
Journal: Nervenarzt Date: 2016-06 Impact factor: 1.214

Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.

Review 1. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

2. Effects of fingolimod treatments on alanine transaminase and aspartate transaminase levels in patients with multiple sclerosis.

3. Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients.

Review 4. Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.

5. Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.

Review 6. [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

7. Initiating oral fingolimod treatment in patients with multiple sclerosis.

8. Adverse Effects of Immunosuppression: Infections.

Review 9. Targeting cells in motion: migrating toward improved therapies.

10. Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.